Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 10/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13823807 | 1.00 | STING1 (0.38) | STING1SLC6A4SLC6A2SLC6A3MEN1 | |
| SCHEMBL10071232 | 0.91 | SLC6A4 (0.37) | SLC6A4SLC6A2SLC6A3MEN1ALDH1A1 | |
| SCHEMBL10041962 | 0.91 | SLC6A4 (0.46) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL10075506 | 0.91 | SLC6A4 (0.46) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL10071233 | 0.81 | SLC6A2 (0.37) | STING1SLC6A4SLC6A2SLC6A3MEN1 | |
| SCHEMBL10050930 | 0.81 | SLC6A2 (0.37) | STING1SLC6A4SLC6A2SLC6A3MEN1 | |
| SCHEMBL20340496 | 0.81 | SLC6A2 (0.37) | STING1SLC6A4SLC6A2SLC6A3MEN1 | |
| SCHEMBL10070677 | 0.71 | SMN1; SMN2 (0.40) | SLC6A4SLC6A2SLC6A3MEN1ALDH1A1 | |
| SCHEMBL20341083 | 0.71 | SLC6A2 (0.44) | SLC6A4SLC6A2SLC6A3MEN1MAPT | |
| SCHEMBL29757853 | 0.71 | SLC6A2 (0.44) | SLC6A4SLC6A2SLC6A3MEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180215702-A1 | ENAMIDE PROCESS | SUNOVION PHARMACEUTICALS INC. | 2018-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180215702-A1 | ENAMIDE PROCESS | ENO1, ENY2, ALKBH2 | STING1 1776/4885SLC6A4 3378/4885SLC6A2 1680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.